Trials / Terminated
TerminatedNCT06039384
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB099280 | Administered as specified in the treatment arm description |
| DRUG | adagrasib | Administered as specified in the treatment arm description |
Timeline
- Start date
- 2023-12-28
- Primary completion
- 2025-04-11
- Completion
- 2025-07-11
- First posted
- 2023-09-15
- Last updated
- 2025-08-03
Locations
14 sites across 4 countries: United States, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06039384. Inclusion in this directory is not an endorsement.